Summary & Overview
HCPCS Q2057: Afamitresgene Autoleucel, Therapeutic Dose
HCPCS Level II code Q2057 designates a therapeutic dose of afamitresgene autoleucel, a cellular gene therapy product, and explicitly bundles leukapheresis and dose preparation procedures into a single per-dose code. This designation matters nationally as cell and gene therapies expand clinical use and payer coverage becomes a central factor in access and cost management for high-cost, one-time or limited-dose treatments. Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for Q2057, what services the code covers, and how it is typically delivered in specialized infusion and hospital outpatient settings. The publication summarizes expected billing scope for a per-therapeutic-dose HCPCS Level II code, common modifiers listed in the input, and identifies where data was not provided. It also outlines the types of benchmarks and policy updates that are relevant for stakeholders: payment bundling for cellular therapies, site-of-service implications, and payer coverage patterns. Clinical teams, revenue cycle managers, and policy analysts will gain clarity on the code's intended use, the service environment, and the payer landscape to inform coding, claims submission, and coverage discussions at a national level.
Billing Code Overview
HCPCS Level II code Q2057 represents afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose. This code describes a single therapeutic dose of a CAR-T cell therapy product that includes the collection procedure (leukapheresis) and the preparation of the cellular dose for administration.
Service type: Cellular gene therapy administration and associated leukapheresis/dose preparation services
Typical site of service: Hospital outpatient infusion centers, specialized ambulatory infusion centers, and academic medical centers with cellular therapy programs
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with relapsed or refractory multiple myeloma who has exhausted standard therapies presents for autologous gene-modified T‑cell therapy with Q2057 (afamitresgene autoleucel). The clinical workflow begins with multidisciplinary evaluation by hematology-oncology and cellular therapy teams to confirm eligibility, obtain informed consent, and plan leukapheresis. Leukapheresis is performed in an outpatient apheresis unit or inpatient specialty unit to collect peripheral blood mononuclear cells, which are shipped to a manufacturing facility. The patient returns for lymphodepleting chemotherapy (often cyclophosphamide and fludarabine) administered in an infusion suite or inpatient oncology unit, followed by infusion of the prepared therapeutic dose of afamitresgene autoleucel in an inpatient or specialized outpatient infusion center depending on institutional protocol and monitoring needs. Post-infusion monitoring includes inpatient observation for cytokine release syndrome and neurotoxicity, routine lab surveillance, supportive care, and scheduled follow-up visits with the cellular therapy team and treating hematologist-oncologist for efficacy assessment and management of adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard unmodified service billing when no special circumstance applies |